Publications by authors named "Javier Afonso"
Article Synopsis
- The study investigates the long-term outcomes of patients with metastatic renal cell carcinoma who achieved a complete response to the TKI sunitinib, revealing little known prior information about this group.
- Data was collected from a registry of 62 patients treated in Spain between 2007 and 2018, with most patients having clear cell histology and previously undergoing nephrectomy.
- Results show that 75% of patients maintained complete response status after 10 years, indicating durable responses across different prognosis groups and metastasis sites.
After progression during first-line treatment in advanced non-small-cell lung cancer (NSCLC), a large percentage of patients are candidates for second-line treatment. The majority do not have epidermal growth factor receptor-activating mutations (EGFRwt). This article reviews the treatment options available for this subpopulation of patients, which includes essentially docetaxel, pemetrexed and erlotinib.
View Article and Find Full Text PDFDocetaxel is the standard first-line chemotherapy for men with metastatic castration-resistant prostate cancer. Until recently, there was no standard therapy after failure of docetaxel treatment. Cabazitaxel has been shown to improve overall survival in this setting.
View Article and Find Full Text PDF